



MORVUS TECHNOLOGY APPOINTS DR ANDREW HEATH AS NON-EXECUTIVE DIRECTOR

February 1st, 2010, Carmarthen. Morvus Technology Limited (“Morvus”), the UK-based pharmaceutical company focused on therapeutics for the oncology market, today announces the appointment of Dr Andrew Heath as Non-Executive Director, effective from January 8th 2010.

Dr Heath has broad experience of European and US healthcare, with an in-depth knowledge of the US and UK capital markets in life sciences. After an early career in academic and clinical medicine in Sweden and at Vanderbilt University in Nashville, TN, Dr Heath held senior research positions with Glaxo, Sweden, and Astra AB. Returning to the US with Astra USA, he was Vice President, Marketing and Sales, before joining Aerogen, Inc as President and CEO. He was Chief Executive Officer of Protherics plc from 1998 to 2008, taking the company from 30 to 350 staff and managing its eventual acquisition by BTG for £220 million. He is currently a non-executive director of Oxford BioMedica plc, XL TechGroup Inc, Anew Inc, Pioneer Technology Inc, and is a director of the BioIndustry Association.

Tony Atkinson, the Chairman of Morvus, said: “I am delighted that Andrew has agreed to join the Morvus Board. His wide experience of the healthcare industry will be an invaluable asset as we grow the company. Andrew knows the Morvus team well and he and I have successfully worked together in the recent past.”

About Morvus Technology Ltd.

Morvus Technology is a privately-owned company engaged in the discovery, development and commercialisation of novel drugs for the oncology market. The Company was established in 2004 and has offices and laboratories near Carmarthen, South West Wales. Morvus has a broad portfolio of technology which is focused on disease areas for which there is a clear, unmet medical need.

CONTACT:

Dr Phil Burke

Chief Executive

pburke@morvus.com

Tel: 01558 667 184